Irvine-based Masimo Corp. announced Tuesday that a new National Institutes of Health (NIH) study shows that its Rainbow SET product may help clinicians assess oxygenation in children suffering with sickle cell disease.
The independent clinical study was presented by the American Thoracic Society in San Diego, indicating that the noninvasive measurement of carboxyhemoglobin (SpCO) and methemoglobin (SpMet) with Masimo Rainbow SET Pulse CO-Oximetry is accurate and may help detect hypoexemia – a potentially life-threatening lack of oxygen in the blood of children with sickle cell disease.
Sickle cell disease is an inherited blood disorder characterized by abnormally shaped red blood cells, which compromise vital blood and oxygen supply to the tissue and organs, causing life-threatening complications.
The presence of carboxyhemoglobin and methemoglobin in a sickle cell patient's blood reduces oxygen supply further because these dyshemoglobins that take the place of normal oxyhemoglobin lack the ability to carry oxygen.
NEXT PAGE >>
Huntington Beach’s Impact Medical rebrands as iTech Medical
AMDL of Tustin seals deal for cancer distribution
Costa Mesa's Oxygen Biotherapeutics inks deal with U.S. Navy
UC Irvine banks $45 million for infectious disease research
NIH: Masimo's SpCO may guage asthma severity in kids